BACKGROUND: Research patients with combined lung cancer (LC) and interstitial lung disease (ILD) is insufficient. The objective of the study was to identify the frequency of such patients and treatments, including best supportive care (BSC), in the real world. METHODS: All patients with LC who were admitted to our hospital over a 5-year period from 2013 to 2017 were retrospectively analysed. RESULTS: In this study, 698 patients with LC were enrolled. A total of 148 (21.2%) suffered from LC and ILD. Seventy-one LC-ILD patients received chemotherapy, and 20 LC-ILD patients received BSC only. Eleven BSC patients whom physicians thought could receive therapy declined treatment. The median survival time of patients who received chemotherapy was 14.3 months (95% confidence interval, 8.5-19.4 months). The median survival time of BSC patients who declined treatment was 7.2 months and that was shorter than that of patients who received chemotherapy. CONCLUSIONS: This study suggests that patients with combined LC and ILD are common (21.2%) in the real world, and there is the possibility that therapy for LC-ILD patients is beneficial. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: Research patients with combined lung cancer (LC) and interstitial lung disease (ILD) is insufficient. The objective of the study was to identify the frequency of such patients and treatments, including best supportive care (BSC), in the real world. METHODS: All patients with LC who were admitted to our hospital over a 5-year period from 2013 to 2017 were retrospectively analysed. RESULTS: In this study, 698 patients with LC were enrolled. A total of 148 (21.2%) suffered from LC and ILD. Seventy-one LC-ILD patients received chemotherapy, and 20 LC-ILD patients received BSC only. Eleven BSC patients whom physicians thought could receive therapy declined treatment. The median survival time of patients who received chemotherapy was 14.3 months (95% confidence interval, 8.5-19.4 months). The median survival time of BSC patients who declined treatment was 7.2 months and that was shorter than that of patients who received chemotherapy. CONCLUSIONS: This study suggests that patients with combined LC and ILD are common (21.2%) in the real world, and there is the possibility that therapy for LC-ILD patients is beneficial. 2019 Journal of Thoracic Disease. All rights reserved.
Entities:
Keywords:
Lung cancer (LC); best supportive care (BSC); chemotherapy; interstitial lung disease (ILD)
Authors: Ivan Le Jeune; Jonathan Gribbin; Joe West; Chris Smith; Paul Cullinan; Richard Hubbard Journal: Respir Med Date: 2007-09-17 Impact factor: 3.415
Authors: Xie Xiaohong; Wang Liqiang; Li Na; Lin Xinqing; Qin Yinyin; Liu Ming; Ouyang Ming; Han Qian; Luo Qun; Li Shiyue; Li Chunyan; Wang Xiaoqian; Yang Shuanying; Huang Wei; Liu Mei; Wang Ping; Zhou Chengzhi Journal: Front Mol Biosci Date: 2021-03-31
Authors: Paolo Cameli; Elena Bargagli; Laura Bergantini; Miriana d'Alessandro; Maria Pieroni; Giovanni A Fontana; Piersante Sestini; Rosa Metella Refini Journal: Int J Mol Sci Date: 2020-08-27 Impact factor: 5.923